Edition:
United Kingdom

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

542.15INR
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
Rs542.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
568,691
52-wk High
Rs728.45
52-wk Low
Rs433.15

Chart for

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.05
Market Cap(Mil.): Rs1,272,113.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 3.50
Yield (%): 0.66

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

UPDATE 1-India's Sun Pharma quarterly profit plunges on weak U.S. sales

* Profit hit by one-time deferred tax adjustment (Adds details)

14 Feb 2018

BRIEF-Sun Pharma Industries Says Qtrly US Finished Dosage Sales Down 35 Pct

* SAYS US FINISHED DOSAGE SALES DURING QUARTER AT US$ 328 MILLION, DOWN 35 PERCENT OVER Q3 LAST YEAR Source text for Eikon: Further company coverage:

14 Feb 2018

India's Sun Pharma Q3 profit slides 75 pct, misses estimates

Feb 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd reported on Wednesday a 75 percent drop in net profit in the quarter ending Dec. 31, well below analysts' estimates.

14 Feb 2018

BRIEF-India's Sun Pharmaceutical Industries Dec-Qtr Consol Profit Down 75 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.65 BILLION RUPEES VERSUS PROFIT OF 14.72 BILLION RUPEES LAST YEAR

14 Feb 2018

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

16 Jan 2018

Indian shares hit record highs for 3rd straight session

Dec 27 Indian shares touched record highs for a third consecutive session on Wednesday, with investors picking pharma stocks such as Sun Pharmaceutical Industries Ltd that have lagged a broader market rally this year.

27 Dec 2017

BRIEF-Sun Pharmaceutical Industries Announces U.S FDA Acceptance Of NDA For OTX-101

* ANNOUNCES U.S FDA ACCEPTANCE OF NDA FOR OTX-101 Source text - http://bit.ly/2BDUZEZ Further company coverage:

27 Dec 2017

BRIEF-Sun Pharmaceutical Industries Reports 12.3 Percent Stake In Scpharmaceuticals As Of November 21

* SUN PHARMACEUTICAL INDUSTRIES LIMITED REPORTS 12.3 PERCENT STAKE IN SCPHARMACEUTICALS INC AS OF NOVEMBER 21 - SEC FILING‍​

27 Nov 2017

BRIEF-Sun Pharma Industries MD says no new updates on Halol; awaiting FDA re-inspection of plants‍​

Nov 14 Sun Pharmaceutical Industries managing director Dilip Shanghvi says:

14 Nov 2017

UPDATE 1-India's Sun Pharma posts profit dive on U.S. pricing pressure

* Q2 profit down 59 pct * Indian sales rise 11 pct * U.S. sales down 44 pct (Adds detail, executive comment) Nov 14 India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other Indian drugmakers, Sun Pharma has had sales dented by rising competition in the generics market and greater pricing scrutiny in the United States,

14 Nov 2017

Earnings vs. Estimates